The hormone somatostatin, which is naturally generated by the body and has a number of actions including inhibiting the release of hormones, is remarkably similar to Octreotide acetate, an injectable medication. Octreotide functions similarly to somatostatin, but it is more slowly destroyed and has a higher inhibitory effect on the release of glucagon, growth hormone, and insulin. Octreotide, like somatostatin, suppresses the production of digestive hormones such serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, and pancreatic polypeptide as well as growth-stimulating hormones, blood flow to the digestive organs, and vasoactive intestinal peptide. Octreotide acetate is used to treat cancer-related symptoms such acute diarrhoea and flushing based on these activities.
Furthermore, acromegaly is treated with Octreotide. Acromegaly is a rare hormonal condition that affects adults and causes excessive growth hormone production, which results in abnormal expansion of the hands, feet, or facial features. Patients with acromegaly see a significant reduction in growth hormone and IGF-I (somatomedin C) levels after using octreotide. Octreotide also inhibits the release of thyroid stimulating hormone (TSH), gallbladder contractility, and bile secretion, among other things. Octreotide acetate was authorised by the FDA in October 1988.
Read More- https://coherentmarketinsightsus.blogspot.com/2023/03/octreotide-is-synthetic-peptide-drug.html
